Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study

BACKGROUND: Real-world data on long-term outcomes of vedolizumab (VDZ) are scarce. OBJECTIVE: To assess long-term outcomes (up to 3 years) of VDZ in treating inflammatory bowel disease (IBD). DESIGN: A nationwide, prospective multicentre extension of a Swedish observational study on VDZ assessing Ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Visuri, Isabella, Eriksson, Carl, Karlqvist, Sara, Lykiardopoulos, Byron, Karlén, Per, Grip, Olof, Söderman, Charlotte, Almer, Sven, Hertervig, Erik, Marsal, Jan, Malmgren, Carolina, Delin, Jenny, Strid, Hans, Sjöberg, Mats, Bergemalm, Daniel, Hjortswang, Henrik, Halfvarson, Jonas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236258/
https://www.ncbi.nlm.nih.gov/pubmed/37274297
http://dx.doi.org/10.1177/17562848231174953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236258/
https://www.ncbi.nlm.nih.gov/pubmed/37274297
http://dx.doi.org/10.1177/17562848231174953

Ejemplares similares